364 related articles for article (PubMed ID: 30213460)
1. Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.
Heikamp EB; Pui CH
J Pediatr; 2018 Dec; 203():14-24.e2. PubMed ID: 30213460
[No Abstract] [Full Text] [Related]
2. Next-Generation Sequencing in Acute Lymphoblastic Leukemia.
Coccaro N; Anelli L; Zagaria A; Specchia G; Albano F
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208040
[TBL] [Abstract][Full Text] [Related]
3. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Della Starza I; De Novi LA; Santoro A; Salemi D; Tam W; Cavalli M; Menale L; Soscia R; Apicella V; Ilari C; Vitale A; Testi AM; Inghirami G; Chiaretti S; Foà R; Guarini A
Leuk Lymphoma; 2019 Nov; 60(11):2838-2840. PubMed ID: 31050551
[No Abstract] [Full Text] [Related]
4. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
6. Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?
Short NJ; Kantarjian H; Jabbour E
Expert Rev Hematol; 2024 Jun; 17(6):189-191. PubMed ID: 38726703
[No Abstract] [Full Text] [Related]
7. Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
Dietrich MF; Collins RH; Gerber DE
JAMA Oncol; 2016 Jan; 2(1):132-3. PubMed ID: 26426250
[No Abstract] [Full Text] [Related]
8. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine in adult acute lymphoblastic leukemia.
Hoelzer D
Haematologica; 2015 Jul; 100(7):855-8. PubMed ID: 26130512
[No Abstract] [Full Text] [Related]
10. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
11. Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
Ishida H; Iguchi A; Aoe M; Takahashi T; Tamefusa K; Kanamitsu K; Fujiwara K; Washio K; Matsubara T; Tsukahara H; Sanada M; Shimada A
Ann Hematol; 2019 Mar; 98(3):657-668. PubMed ID: 30446805
[TBL] [Abstract][Full Text] [Related]
12. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia.
Brennan L; Narendran A
Stem Cells Dev; 2019 Oct; 28(19):1277-1287. PubMed ID: 31364487
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.
Lejman M; Kuśmierczuk K; Bednarz K; Ostapińska K; Zawitkowska J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575992
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
[TBL] [Abstract][Full Text] [Related]
16. Childhood acute lymphoblastic leukemia.
Pui CH; Relling MV; Campana D; Evans WE
Rev Clin Exp Hematol; 2002 Jun; 6(2):161-80; discussion 200-2. PubMed ID: 12196214
[TBL] [Abstract][Full Text] [Related]
17. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
19. Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia.
Aleem A; Haque AR; Roloff GW; Griffiths EA
Curr Hematol Malig Rep; 2021 Oct; 16(5):394-404. PubMed ID: 34613552
[TBL] [Abstract][Full Text] [Related]
20. Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation.
Xu H; Shu Y
Methods Mol Biol; 2018; 1754():387-413. PubMed ID: 29536454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
